You are here: Industry Insights > pipeline

News List

Amgen, Molecular Partners Enter Immunotherapy Alliance contractpharma
December 21, 2018
Amgen and Molecular Partners AG, a biotech company developing DARPin therapeutics, have entered a collaboration and license agreement for the clinical development and commercialization of MP0310...
New Pfizer CEO's top priorities? Think China and pipeline, not deals fiercepharma
December 20, 2018
Wondering how much incoming Pfizer CEO Albert Bourla is going to shake things up at the drugmaker? Not much, apparently. “Ian’s vision is my vision,” Bourla said of predecessor Ian Read at an analyst lunch where he sketched out his plans.
New Pfizer CEO's top priorities? Think China and pipeline, not deals fiercepharma
December 20, 2018
Wondering how much incoming Pfizer CEO Albert Bourla is going to shake things up at the drugmaker? Not much, apparently. “Ian’s vision is my vision,” Bourla said of predecessor Ian Read at an analyst lunch where he sketched out his plans.
AC Immune & Lilly Partner for Alzheimer's contractpharma
December 13, 2018
AC Immune SA and Eli Lilly and Company have signed a license and collaboration agreement to research and develop tau aggregation inhibitor small molecules for the potential treatment of Alzheimer's disease
GSK wraps up promised Horlicks sell-off in £3.1B deal with Unilever fiercepharma
December 04, 2018
After weighing options and offers for its Horlicks drinks brand in India for several months, GlaxoSmithKline signed off on a £3.1 billion sale to Unilever. The cash will help GSK cover the cost of its
ORIC Pharma Appoints CBO firstwordpharma
November 27, 2018
Matt Panuwat has been appointed chief business officer at ORIC Pharmaceuticals, a clinical-stage oncology company focused developing novel therapies against treatment-resistant cancers.
Is Moderna prepping for biotech's biggest-ever IPO? fiercebiotech
September 14, 2018
Modera Therapeutics is one of a select group of biotech "unicorns."
Atreca bags $125M as solid tumor trial comes into view fiercebiotech
September 13, 2018
Atreca’s cranking of its discovery engine has uncovered more than 1,000 antibodies.
Activist pushes Acorda to sell, figuring pipeline's too risky to offset Ampyra loss fiercepharma
August 08, 2017
A New York hedge fund, Scopia Capital Management, wants Acorda to put itself up for sale
Pipeline Drug Offers Promise in Treatment of Platinum-Resistant Ovarian Cancer americanpharmaceuticalreview
April 19, 2017
According to research and consulting firm GlobalData, mirvetuximab soravtansine, a drug currently in the trial phase by ImmunoGen, has the potential to solve an unmet medical need for patients with platinum-resistant ovarian cancer.

Previous page 1 2 3 Next page